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Abstract
Objectives—Highly active antiretroviral therapy (HAART) provision to eligible HIV-infected 
pregnant and post-partum women is critical for optimizing maternal health. We assessed the 
impact of maternal HAART on HIV-free survival of breastfed infants in Malawi.
Methods—The Post-Exposure Prophylaxis of Infants (PEPI)-Malawi trial (2004-2009) enrolled 
mothers/infants during labor or immediately post-partum to evaluate 14-week extended infant 
antiretroviral prophylaxis for preventing HIV transmission through breastfeeding. Mothers 
meeting national HAART guidelines were referred for therapy. Child HIV-free survival--survival 
without HIV infection --was compared by maternal HAART status.
Results—Overall, 3,022 mother-infant pairs contributed 4,214 infant/person-years (PY) at-risk 
for HIV infection or death, with 532 events (incidence 12.6/100 PY, 95% confidence interval [CI] 
11.6-13.7). During follow-up, 349 mothers were HAART initiated; 581 remained HAART naïve 
with CD4 cell counts <250 cells/mm3, and 2,092 were never HAART-eligible. By three months, 
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11% of infants with HAART naïve mothers (CD4<250) were infected with HIV or died versus 7% 
of infants of HAART-initiated mothers and 4% of infants of HAART-ineligible mothers. Maternal 
HAART was associated with a 46% reduction in infant HIV infection or death as compared to 
infants with HAART naïve mothers (CD4<250) (adjusted Hazards Ratio: 0.54,95% CI 0.36-0.81). 
Among HIV-exposed, uninfected infants, breastfeeding, but not HAART, was significantly 
associated with decreased child mortality.
Conclusions—HIV infection and mortality are high during the first 3 months post-partum in 
infants of mothers with advanced HIV, and rapid maternal HAART initiation can significantly 
improve HIV-related infant outcomes.
Keywords
HIV-1; prevention of mother-to-child transmission; highly active antiretroviral therapy; child 
survival; breastfeeding
INTRODUCTION
Breastfeeding is the cornerstone of infant survival in many resource-constrained settings, but 
is also associated with a significant risk of mother-to-child HIV transmission (MTCT) (1). 
Clinical trials have demonstrated that antiretroviral drugs given to infants during 
breastfeeding or to lactating mothers significantly reduce postnatal HIV transmission (2-8). 
The World Health Organization's (WHO) HIV treatment guidelines continue to change in 
light of new evidence and now recommend starting adult highly active antiretroviral therapy 
(HAART) at ≤500 cells/mm3 or WHO Stage 3 or 4 disease, and starting all pregnant women 
on lifelong HAART independent of CD4 count or clinical indication (Option B+), or when 
not feasible offering maternal HAART for women not otherwise indicated for treatment 
throughout the pregnancy and breastfeeding periods (Option B) (9).
The Post-Exposure Prophylaxis of the Infant (PEPI) trial was conducted prior to the WHO 
updated guidelines and prior to the introduction of Option B+ in Malawi. PEPI demonstrated 
that 14 week extended infant antiretroviral prophylaxis significantly reduced postnatal 
MTCT (10). We previously reported that receipt of postnatal maternal HAART by women 
eligible for treatment significantly reduced postnatal MTCT risk between 14 weeks (after 
infant prophylaxis ceased) and 24 months compared to women eligible for treatment who 
did not receive HAART (11).
Preventing HIV infection alone is not the ultimate goal of successful prevention of MTCT 
(PMTCT) programs however. HIV-free survival –PMTCT coupled with a reduction in all-
cause child mortality-- is endorsed by the WHO as the indicator critical to the success of 
PMTCT interventions and to the formulation of infant feeding guidelines (12). Assessment 
of the impact of maternal HAART on infant outcomes should thus consider the HIV-free 
survival endpoint. Furthermore, several reports indicate that HIV-exposed but uninfected 
children experience adverse outcomes at higher rates than HIV-unexposed children and that 
low maternal CD4 cell count during pregnancy is associated with higher mortality in HIV-
exposed, uninfected children (13-16).
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The primary objective of this analysis was to assess the impact of maternal HAART within 
the PEPI trial on child HIV-free survival; the secondary objective was to assess the impact 
of maternal HAART on 24-month child survival amongst HIV-exposed, uninfected infants. 
These data preceding the current recommendations for PMTCT may provide preliminary 
evidence of the potential impact of current PMTCT guidelines – particularly among women 
with lower CD4 cell counts.
MATERIALS AND METHODS
Study Design
This is a secondary analysis of data collected as part of the PEPI clinical trial which enrolled 
participants between April 2004-December 2007 and followed participants to September 
2009. The trial has been described previously (2). Briefly, the PEPI trial screened pregnant 
women who attended antenatal clinics and labor wards in Blantyre, Malawi for HIV 
infection. HIV-infected mothers intending to breastfeed and not previously initiated on 
HAART were enrolled and infants were randomized at birth to receive one of three 
treatment strategies for PMTCT: i) single-dose nevirapine (sdNVP) at birth, plus one week 
of zidovudine (ZDV) (control arm); ii) control treatment plus daily NVP to age 14 weeks; or 
iii) control treatment plus daily NVP+ZDV to age 14 weeks.
Infant HIV infection status was assessed at 1, 6, 9 and 14 weeks after birth, and then 
subsequently at 6, 9, 12, 15, 18 and 24 months. HIV-testing was performed using DNA 
polymerase chain reaction (PCR) (Roche Amplicor, version 1.5, Roche Molecular Systems) 
through the first 12 months and then using HIV serology from 15 months forward. HIV 
infection was defined as a confirmed positive HIV test (PCR or serology). Maternal CD4 
cell count was measured at delivery and 14 weeks, 12 months and 24 months post-partum.
When the PEPI-Malawi trial began in April 2004, antiretroviral treatment (ART) was not 
widely available. The Malawian government began scale-up of their free national treatment 
program in 2004 and involved HAART eligibility based on CD4 count <250 cells/mm3 or 
WHO Clinical Stage 3 or 4 disease (17). The national treatment program was introduced 
mid-way through the PEPI trial. Upon introduction of the national ART program, post-
partum women eligible for treatment per national guidelines who participated in PEPI were 
referred to the government ART clinics. At the time when government ART program 
implementation started, coverage of ART-eligible individuals was largely determined by 
logistical factors. For example, the number of eligible participants in the government 
program was restricted to 150 new patients per month in Blantyre and access to treatment 
was on a first-come first-served basis (18). Therefore, the majority of eligible women from 
the PEPI study who received HAART from the government program started after 14 weeks 
post-partum. Assessment of maternal HAART use was based on maternal history collected 
at each visit on structured case report forms and verified using concomitant medication 
treatment logs and clinic records.
Women enrolled in the PEPI trial were regularly counseled to exclusively breastfeed for the 
first six months after delivery and initially advised to stop breastfeeding after 6 months. 
Following revisions in WHO breastfeeding guidance however, counseling was revised 
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during the trial to advise women to breastfeed past 6 months if they could not safely 
substitute for breastfeeding. Breastfeeding status was collected at each study visit and was 
heterogeneous after six months post-partum due to guideline changes.
The PEPI study protocol was reviewed and approved by the relevant institutional review 
boards in Malawi and the United States (Research and Ethics Committee, University of 
Malawi College of Medicine; institutional review boards of the Johns Hopkins Bloomberg 
School of Public Health, Baltimore, and the Centers for Disease Control and Prevention, 
Atlanta). All women provided written informed consent.
Endpoint and Exposure Assessment
The primary outcome in this analysis is child HIV-free survival up to 24 months – where 
HIV-free survival is defined as survival to age 24 months without HIV infection. HIV-free 
survival is used to assess infant outcomes as breastfeeding exposes infants to HIV-infection, 
but also provides other child survival benefits. Infants contributed time-at-risk to the HIV-
free survival analyses from time of birth until the point of HIV infection, mortality, loss-to-
follow-up or administrative censoring at 24 months or the completion of the study, 
whichever occurred first. HIV infection was assigned to the visit of HIV diagnosis. Infants 
were included in the analysis if they were HIV uninfected at birth (PCR DNA negative).
To examine any additional benefit of maternal HAART beyond PMTCT, we separately 
assessed predictors of child mortality within the first 24 months of life among the HIV-
exposed and uninfected children. The models in this analysis compared relative hazards of 
time to child-death across covariates. Infants HIV uninfected at birth contributed time-at-
risk from birth until they had the outcome (mortality), were infected with HIV (and 
censored), lost to follow-up, administratively censored at 24 months, or the completion of 
the study. Results were stratified by 0-6 months postpartum and >6 months-24 months as 
nearly all women breastfed during the first 6 months post-partum and breastfeeding 
practices varied after 6 months.
The primary exposure of interest for the analyses was maternal HAART and CD4 status. 
Mothers were classified according to whether they were eligible for treatment and initiated 
on HAART at government clinics during study follow-up (HAART initiated), whether they 
had a CD4 count <250 cells/mm3 during study follow-up and remained HAART naïve for 
any reason (e.g. the woman did not attend the clinic or the clinic did not initiate treatment), 
or whether their CD4 count remained ≥250 cells/mm3 throughout study follow-up (HAART 
ineligible). As this was a longitudinal study, HAART exposure and CD4 classification were 
time-varying and although no women began the study on HAART, women could contribute 
time-at-risk to different exposure categories as treatment was later initiated among some 
mothers.
Statistical Analyses
Differences in means, medians and proportions were compared using analysis of variance 
(ANOVA), Wilcoxon rank-sum tests and chi-squared statistics respectively. Visual 
assessments were used to assess outliers and to confirm the normality of the distribution of 
continuous variables for each group for the ANOVA analyses; Levene's test was used to 
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assess homogeneity of variances. Medians and non-parametric Wilcoxon rank-sum tests 
were reported when ANOVA assumptions were not met. Kaplan-Meier survival curves were 
plotted to assess child HIV-free survival across maternal HAART eligibility and treatment 
groups. Cox proportional hazards (PH) models were used to assess bivariate and 
multivariate predictors of HIV infection or child mortality in the cohort and separately to 
assess predictors of child mortality amongst HIV-exposed, uninfected children. In addition 
to the exposure of maternal HAART status, the covariates for both maternal and infant 
characteristics, including maternal age, body mass index (BMI), viral load and infant birth 
weight and household characteristics including electricity and running water. Covariates 
were retained for the multivariate models based on known associations or statistical 
associations of p≤0.10. Models also controlled for treatment assignment in the parent 
randomized clinical trial. As the two infant prophylaxis arms (NVP alone or NVP+ZDV) 
significantly reduced HIV infection and were equally effective in the PMTCT in the PEPI 
trial as compared to the control arm (2), the two infant prophylaxis arms were combined and 
adjusted for in this analysis. Proportionality of hazards were assessed using Schoenfeld 
residuals. All analyses were conducted using Stata 12.1 (StataCorp, College Park, Texas, 
USA).
RESULTS
Overall, 3,022 mother-infant pairs were included in the analysis. Amongst the 349 women 
starting HAART during study follow-up, the mean CD4 count at HAART initiation was 167 
cells/mm3 (standard deviation [sd]: 100); 21% of women initiating HAART had CD4 counts 
≤100 cells/mm3. The mean CD4 count of women eligible, but not yet initiated on HAART 
was 186 cells/mm3 (sd: 55); 10% had CD4 counts ≤100 cells/mm3 (p<0.01). As no women 
were initiated on HAART at enrollment into the study, Table 1 compares characteristics of 
women according to their CD4 cell count and HAART status at the end of follow-up. 
Women across treatment categories were different by baseline maternal age and body mass 
index (BMI), CD4 cell count (at baseline and endline), baseline log viral load, educational 
attainment, infant birth weight and breastfeeding duration.
Infants contributed 4,214 person-years (PY) at-risk for HIV infection or death and 
experienced 532 events (incidence rate 12.6/100 PY, 95% confidence interval [CI] 
11.6-13.7). Figure 1 shows the differences in Kaplan-Meier estimates for child HIV-free 
survival by time-varying HAART and CD4 status. Infants of mothers with CD4 counts ≥250 
cells/mm3 throughout study follow-up (HAART ineligible) had the best survival outcomes, 
followed by infants with HAART initiated mothers. Infants of mothers with CD4 cell counts 
<250 cells/mm3 who remained HAART naïve during follow-up had the lowest HIV-free 
survival. Overall at 24 months, cumulative HIV-free child survival ranged from 70.4% 
among infants of HAART-naïve mothers with CD4 counts <250 cells/mm3 to 82.4% among 
infants of mothers ineligible for HAART per national guidelines.
Baseline log viral load, maternal HAART status, infant birth weight and infant prophylaxis 
were associated with HIV-free survival in the bivariate Cox models (Table 2). Maternal 
HAART was associated with a 45% reduction in infant HIV infection or death in the 
adjusted model compared with infants of mothers who were HAART naïve and had CD4 
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counts <250 cells/mm3. Infants whose mothers were ineligible for HAART per national 
guidelines (CD4 ≥250 cells/mm3) also had improved HIV-free survival outcomes in the 
adjusted analysis (33% reduction in HIV infection or death) as compared to infants with 
HAART naïve mothers with CD4 counts <250 cells/mm3. Because viral load measurements 
were missing for 296 women, the multivariate analyses were repeated amongst the full 
cohort excluding viral load, however inferences were unchanged.
To examine the impact of maternal HAART on child HIV-free survival according to 
breastfeeding status, we additionally conducted stratified Cox PH analyses of child HIV-free 
survival over two time periods, 0-6 months when nearly all women reported breastfeeding 
(88.6% at 6 months), and 6-24 months when women initially started cessation of 
breastfeeding. In both time periods, the risk of HIV infection or death was lower amongst 
infants with mothers initiated on HAART or ineligible for HAART, as compared to infants 
with mothers HAART naïve with CD4 cell counts <250 cells/mm3 (results not shown). In 
these models the magnitude of the protective effect of HAART for infants with treated 
mothers as compared to infants with eligible, but HAART naïve mothers was similar during 
the first 6 months after birth when nearly all mothers were breastfeeding (adjusted Hazard 
Ratio [aHR] 0.52 [95% CI: 0.25-1.08], p=0.08), to the effect observed in the model from 
6-24 months when breast-feeding status was mixed (aHR 0.51 [95% CI: 0.29-0.89], 
p=0.02). Both of these models adjusted for maternal BMI, maternal viral load, infant birth 
weight and infant prophylaxis treatment arm; the 6-24 month model additionally adjusted 
for time-varying breastfeeding status as breastfeeding practices varied across women during 
this period. In these same two models, infants with mothers ineligible for HAART also 
trended toward having a reduced risk of infant HIV infection or death during 0-6 months 
(aHR 0.66 [95% CI: 0.51-0.85], p<0.01), and the 6-24 month time period (aHR 0.71 [95% 
CI: 0.50-1.01], p=0.06) as compared to infants of HAART naïve mothers with CD4 counts 
<250 cells/mm3.
HIV-exposed, but uninfected children in the PEPI cohort had more favorable child survival 
outcomes as compared to HIV-infected children. Even so, by two years post-partum, 
mortality amongst HIV-uninfected children whose mothers were eligible for HAART per 
national guidelines was greater than 10% (results not shown). Cox PH models were run to 
assess predictors of child mortality among HIV-exposed, but uninfected children (Table 3). 
Maternal viral load and maternal death were strongly associated with child mortality in the 
first six months in bivariate analyses, while an increase in infant birth weight was protective 
against child mortality. In the multivariate analysis, maternal viral load and infant birth 
weight remained significantly associated with child mortality during the 0-6 month strata. 
For infants >6 months, running water in the household and breastfeeding were associated 
with a statistically significant reduction in child mortality amongst HIV-exposed, uninfected 
infants. Maternal HAART use was not associated with child mortality in this sub-analysis.
DISCUSSION
This study demonstrates the substantial effect of maternal HAART on improving HIV-free 
child survival outcomes in women with advanced HIV disease requiring therapy. Women 
with high CD4 cell counts who were ineligible for HAART had the best infant survival 
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outcomes in the crude analysis. After controlling for maternal viral load and other important 
factors that differed amongst women by HAART status, infants with mothers on HAART 
and infants of mothers who were not yet eligible for HAART had respectively, an estimated 
45% and 33% reduction in HIV infection or death as compared to infants with HAART 
naïve mothers with CD4 counts <250 cells/mm3 (Table 2). Greater than 10% of infants with 
mothers eligible for but not receiving HAART were infected with HIV or died by three 
months of age (Figure 1). The rapid initiation of HAART as part of the Option B+ program 
will hopefully eliminate this treatment delay and offer HIV-free child survival benefits for 
infants of women with low CD4 cell counts. Whether initiation of HAART would also 
provide benefit to infants of women with higher CD4 counts is unknown; in the HPTN 046 
trial, HIV-free survival rates at 18 months were not significantly different for infants of 
women on HAART per national guidelines and infants of women with CD4 count ≥350 
cells/mm3 not receiving HAART (96.3% and 95.2%, respectively, p=0.46) (19). However, 
while progression to CD4 <350 cells/mm3 is slow in women with high CD4 cell counts 
(CD4 ≥500-550 cells/mm3), nearly a third of women with CD4 350-499 cells/mm3 
experience a drop below 350 cells/mm3 within 1-2 years postpartum, and the threshold for 
starting treatment is often missed in HIV-infected women after delivery (20, 21). Thus, 
given programmatic difficulties in ensuring appropriate postpartum follow-up of women, 
starting all women on HAART provides an alternative to ensure women who need therapy 
receive it.
Maternal HAART was not directly associated with reduced child mortality among HIV 
exposed, uninfected children, suggesting that child HIV-free survival benefits are largely 
conferred through prevention of mother-to-child transmission. However the PEPI data 
demonstrates indirect evidence for the potential of maternal HAART in reducing child 
mortality as earlier HAART initiation would result in decreased maternal mortality and 
increased breastfeeding duration, which were both independently associated with reductions 
in child mortality (Table 3). Indeed a major finding from the analysis of HIV-uninfected, 
exposed infants was that breastfeeding between the ages 6-24 months was associated with a 
95% decrease in risk of child mortality (aHR 0.05 [95% CI 0.01-0.21]).This highlights the 
importance of breastfeeding for child survival amongst uninfected, exposed infants and 
underscores the benefits of breastfeeding in this environment when MTCT risks can be 
minimized through HAART initiation.
The study has some limitations. Because women were initiated on HAART at local clinics 
and not through study services, the study was only able to ascertain whether women were 
currently on HAART and not the exact date of HAART initiation. Thus we cannot account 
for any expected delay in the positive effect of HAART from time of HAART initiation to 
time of viral load suppression. Furthermore, among women with low CD4 cell counts (<250 
cells/mm3), HAART was not universally initiated within the public sector and it is possible 
that women who were more ill may have been more likely to receive HAART. In fact, 
women initiated on HAART in our analysis were more likely to have CD4 counts <100 
cells/mm3 at baseline as compared to women with low CD4 cell counts who remained 
HAART naïve. As a result, if women initiated on HAART were actually more ill than 
HAART naïve women with low CD4 counts, confounding-by-indication would be present in 
Schwartz et al. Page 7









our analysis and we may have underestimated the protective effect of HAART in this 
population. There also may have been important unmeasured confounders such as 
geographic proximity to the clinic, which may have been associated with both initiation of 
HAART amongst eligible women and better infant outcomes. However a previous analysis 
from our cohort did not find any demographic factors to be associated with HAART 
initiation amongst post-partum women (18).
Despite the limitations, these results clearly demonstrate the importance of maternal HIV 
disease status on child HIV-free survival. Infants of mothers not meeting national treatment 
eligibility at the time of the study had the best HIV-free survival; for infants of mothers 
meeting treatment eligibility criteria, our results demonstrate the crucial impact of initiating 
maternal HAART on the HIV-free survival of children. Although we had expected greater 
survival benefits beyond PMTCT than what were observed, this finding may be due to the 
overall poorer health status of women eligible for HAART. Infants of mothers with higher 
CD4 cell counts had the best HIV-free survival outcomes. This suggests that even though a 
protective effect of HAART above PMTCT was not directly observed in this cohort of 
women initiating treatment <250 cells/mm3, earlier initiation of HAART at higher CD4 
counts to prevent high viral burden, greater immune suppression and other concomitant 
maternal morbidities may prevent HIV transmission and independently maximize child 
survival outcomes.
The current Option B+ program in Malawi recommending lifelong HAART for pregnant 
and postpartum breastfeeding women was not introduced in Malawi based on effectiveness 
data from the field. So far only coverage and retention components of the Malawi program 
have been reported (22-24). In the PEPI study which preceded Option B+, high rates of HIV 
infection and mortality occurred during the first 3 months post-partum, reinforcing the need 
to treat earlier those women requiring HAART and providing evidence in support of Option 
B or B+ strategies which facilitate immediate HAART initiation without need to wait for 
CD4 test results. Importantly, the benefits of HAART in mothers with advanced HIV 
disease for infant HIV-free survival persist after 6 months post-partum when breastfeeding 
practices are more variable. For women with higher CD4 cell counts, initiation of HAART 
regardless of CD4 count would hopefully avoid the additional delays observed in starting 
ART after CD4 cell decline because of lack of immunologic monitoring in the postpartum 
period (21). A critical component of the Option B+ strategy related to both maternal and 
infant survival will be to ensure retention in care and provide support for adherence to 
therapy, particularly among women who would otherwise be not starting on HAART for 
their own health (23).
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Table 1
Characteristics of mothers and infants according to final maternal treatment category, PEPI Study, Malawi, 
2004-2009 (n=3,022)
HAART naïve CD4 
<250 cells/mm3
HAART initiated HAART ineligible p-value
Baseline Maternal & Household Characteristics n=581 n=349 n=2092
Control arm, n (%) 188 (32.4) 98 (28.1) 683 (32.6) 0.24
Age, Mean yrs (SD) 27.2 (4.6) 28.3 (4.7) 25.7 (4.7) <0.01
Body Mass Index, Mean kg/m2 (SD) 23.6 (3.5) 23.6 (3.6) 23.9 (4.0) 0.05
CD4 count at enrollment, Median cells/mm3, (IQR) 211 (157-249) 174 (112-242) 485 (374-654) <0.01
Log10 viral load, Mean copies/ml (SD)a 4.3 (0.8) 4.4 (0.8) 3.9 (0.8) <0.01
Married, n (%) 538 (92.6) 314 (90.0) 1929 (92.2) 0.31
Parity, Median (IQR) 3 (2-4) 4 (3-5) 3 (2-4) <0.01
Education, n (%)
    No schooling 66 (11.4) 43 (12.3) 206 (9.8)
    Grade 1-8 289 (49.7) 175 (50.1) 1156 (55.3) 0.02
    Secondary or beyond 226 (38.9) 131 (37.6) 730 (34.9)
Electricity in the house, n (%) 192 (33.1) 117 (33.5) 682 (32.6) 0.93
Running water, n (%) 144 (24.8) 74 (21.2) 449 (21.5) 0.21
Endline Maternal Characteristics
Final CD4 count, Median cells/mm3, (IQR) 209 (154-252-) 270 (177-375) 493 (372-662) <0.01
Infant Characteristics
Combined infant treatment arm (NVP alone + NVP/ZDV), n 
(%)
393 (67.6) 251 (71.9) 1409 (67.4) 0.24
Birth weight, Mean grams (SD) 2993 (470) 2970 (450) 3052 (436) <0.01
Breastfeeding duration, Median days (IQR) 181 (98-188) 182 (180-185) 182 (165-270) <0.01
NVP = Nevirapine; ZDV = Zidovudine; SD = Standard deviation; IQR = Interquartile range. Differences in means, medians and proportions were 
compared using analysis of variance (ANOVA), Wilcoxon rank-sum tests and chi-squared statistics respectively.
aViral load n=2726
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Table 2
Bivariate and adjusted proportional hazards models for HIV infection or child mortality, PEPI Study, Malawi, 
2004-2009, n=2726
Characteristics Proportional Hazards [95% CI] p-value Adjusted Proportional Hazards 
[95% CI]a
p-value
Maternal age, yrs 1.00 [0.98-1.02] 0.93
Electricity in the house, yes vs. no 0.88 [0.73-1.06] 0.19
Running water, yes vs. no 0.88 [0.71-1.09] 0.24
Baseline maternal BMI, kg/m2 0.97 [0.94-0.99] 0.01 0.99 [0.96-1.02] 0.45
Baseline viral load, log10 (copies/ml) 1.66 [1.47-1.88] <.01 1.63 [1.44-1.85] <0.01
Time-varying maternal HAART status
    HAART naïve, CD4 <250 cells/mm3 REF REF
    HAART initiated 0.59 [0.41-0.86] <0.01 0.55 [0.37-0.82] <0.01
    HAART ineligible, CD4 ≥250 cells/mm3 0.51 [0.42-0.61] <0.01 0.67 [0.55-0.82] <0.01
Infant birth weight, per 1 kgb
    0-6 months 0.51 [0.39-0.67] <0.01 0.58 [0.44-0.78] <0.01
    >6 months – 24 months 0.79 [0.60-1.04] 0.10 0.92 [0.69-1.21] 0.54
Control armb REF REF
Combined infant prophylaxis arm
    0-6 months 0.59 [0.45-0.76] <0.01 0.57 [0.44-0.75] <0.01
    >6 months – 24 months 1.07 [0.82-1.41] 0.60 1.04 [0.79-1.36] 0.78
a
Model restricted to women with available baseline viral loads
bVariable is interacted with time due to violation of the proportional hazards assumption; results are provided for the effect of the variable at 0-6 
months and the effect at >6-24 months.
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Table 3
Risks factors for child mortality amongst HIV-exposed, uninfected children, PEPI Study, Malawi, 2004-2009.
0-6 Months, n=2694
Hazard Ratio [95% CI] p-value Adjusted Hazard Ratio [95% CI] p-value
Maternal age, per one year 0.97 [0.92-1.01] 0.15
Maternal BMI, per kg/m2 0.98 [0.92-1.04] 0.45
Maternal viral load at baseline, log (copies/ml) 1.73 [1.27-2.36] <0.01 1.49 [1.08-2.05] 0.02
Maternal HAART
    HAART naïve, CD4 <250 cells/mm3 REF REF
    HAART initiated 0.78 [0.18-3.34] 0.74 0.50 [0.07-3.81] 0.51
    HAART ineligible, CD4 ≥250 cells/mm3 0.52 [0.33-0.84] 0.01 0.80 [0.46-1.37] 0.41
Maternal death 8.18 [3.76-17.78] <0.01 2.22 [0.86-5.73] 0.10
Infant birth weight, per kg 0.31 [0.20-0.47] <0.01 0.38 [0.24-0.62] <0.01
Infant prophylaxis treatment arm 0.89 [0.56-1.43] 0.64
Electricity in the house 1.00 [0.63-1.61] 0.99
Running water 1.29 [0.78-2.12] 0.33 1.52 [0.90-2.55] 0.12
>6 months – 24 months, n=2311
Hazard Ratio [95% CI] p-value Adjusted Hazard Ratio [95% CI] p-value
Maternal age, per one year 1.00 [0.97-1.04] 0.90
Maternal BMI, per kg/m2 1.01 [0.97-1.05] 0.64
Maternal viral load, log(copies/ml) 1.14 [0.93-1.39] 0.20 1.11 [0.91-1.37] 0.31
Maternal HAART
    HAART naïve, CD4 <250 cells/mm3 REF REF
    HAART initiated 1.28 [0.74-2.21] 0.38 1.03 [0.58-1.84] 0.92
    HAART ineligible, CD4 ≥250 cells/mm3 0.90 [0.60-1.36] 0.24 0.94 [0.61-1.47] 0.80
Maternal death 1.00 [0.37-2.68] 0.99 0.68 [0.21-2.15] 0.51
Infant birth weight, per kg 0.72 [0.51-1.01] 0.06 0.78 [0.54-1.13] 0.19
Infant prophylaxis treatment arm 0.93 [0.66-1.30] 0.66
Electricity in the house 0.79 [0.56-1.12] 0.19
Running water 0.62 [0.40-0.96] 0.03 0.57 [0.36-0.90] 0.02
Breastfeeding status
    No longer breastfeeding REF REF
    Currently breastfeeding 0.05 [0.01-0.19] <0.01 0.05 [0.01-0.21] <0.01
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